Quarterly report pursuant to Section 13 or 15(d)

Royalty Purchase Agreements - Summary of Acquisition of Royalty Rights (Details)

v3.19.3
Royalty Purchase Agreements - Summary of Acquisition of Royalty Rights (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2019
USD ($)
Royalty Purchase Agreement [Line Items]  
Balance at December 31, 2018 $ 15,000 [1]
Balance at September 30, 2019 34,375
Royalty Purchase Agreement [Member]  
Royalty Purchase Agreement [Line Items]  
Balance at December 31, 2018 15,000
Balance at September 30, 2019 34,375
Royalty Purchase Agreement [Member] | Bioasis [Member]  
Royalty Purchase Agreement [Line Items]  
Acquisition of royalty rights 375
Royalty Purchase Agreement [Member] | Aronora [Member]  
Royalty Purchase Agreement [Line Items]  
Acquisition of royalty rights 9,000
Royalty Purchase Agreement [Member] | Palobiofarma [Member]  
Royalty Purchase Agreement [Line Items]  
Acquisition of royalty rights $ 10,000
[1] The consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.